CareDx, Inc (CDNA) vs Enliven Therapeutics, Inc. (ELVN)
A side-by-side comparison of CareDx, Inc and Enliven Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CDNA
CareDx, Inc
$63.79HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
ELVN
Enliven Therapeutics, Inc.
$42.39HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — CDNA vs ELVN
growth of $100 · dividends reinvested · last 7yCDNA +206.4% (+17.3%/yr)ELVN -24.2% (-3.9%/yr)CDNA compounded faster over this window
CDNA ELVN
CDNA vs ELVN: by the numbers
- •CDNA is the larger company ($3.30B vs $3.03B market cap).
- •CDNA is profitable (24.23% net margin) while ELVN runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | CDNA | ELVN |
|---|---|---|
| P/E ratio | 30.80 | N/A |
| Forward P/E | 53.26 | N/A |
| P/S ratio | 7.20 | N/A |
| P/B ratio | 7.75 | 3.38 |
| EV / EBITDA | 189.34 | N/A |
| FCF yield | 2.58% | N/A |
Profitability
| Metric | CDNA | ELVN |
|---|---|---|
| Gross margin | 70.58% | 0.00% |
| Operating margin | -0.92% | 0.00% |
| Net margin | 24.23% | 0.00% |
| ROE | 26.08% | -11.83% |
| ROIC | -0.93% | -13.88% |
Growth (annualized)
| Metric | CDNA | ELVN |
|---|---|---|
| Revenue CAGR (5Y) | 12.56% | N/A |
| Total return CAGR (5Y) | 1.33% | 24.57% |
Frequently asked
- Is CDNA or ELVN more profitable?
- CDNA runs the higher net margin — CDNA at 24.23% versus ELVN at 0.00%.
- How have CDNA and ELVN total returns compared?
- Over the past 5 years, CDNA delivered 1.33% and ELVN delivered 24.57% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
CareDx P/E ratioCareDx ROEEnliven Therapeutics ROECareDx operating marginEnliven Therapeutics operating marginCareDx revenue growthEnliven Therapeutics revenue growthCareDx free cash flowEnliven Therapeutics free cash flow
CareDx & Enliven Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.